Ridgefield, CT, April 5, 2012 – New data from Boehringer Ingelheim's hepatitis C virus (HCV) clinical development program, HCVerso™, have been accepted for presentation at the International Liver Congress™ 2012, the 47th Annual Meeting of the European Association for the Study of the Liver (EASL), taking place April 18 – 22 in Barcelona, Spain. Data from SOUND-C2, a Phase 2b trial evaluating an investigational interferon-free HCV treatment, have been selected for inclusion in official EASL press office activities.
Selected for Oral Presentation and Inclusion in Official EASL Press Office Activities
Boehringer Ingelheim's abstracts not included in EASL media activities can be accessed through the EASL website, www.easl.eu. The Boehringer Ingelheim data included in EASL press office activities will remain under embargo until the time of presentation on April 21 at 8:30 a.m. CEST (2:30 a.m. EDT).
Collectively, these data underscore the company’s focus on finding answers to the challenges faced by HCV patients.
Selected for Oral Presentation and Inclusion in Official EASL Press Office Activities
| Title | Lead Author | Presentation details |
|---|---|---|
| SOUND-C2 interim results: SVR4 and SVR12 with an interferon-free regimen of BI 201335 and BI 207127 +/- ribavirin, in treatment-naive patients with chronic genotype-1 HCV infection | S. Zeuzem | Oral Abstract Date: Sat, April 21 Time: 8:30 - 8:45 a.m. CEST/ 2:30 - 2:45 a.m. EDT EASL press conference Date: Thur, April 19 Time: 11:00 a.m. - 12:00 p.m CEST/ 5:00 - 6:00 a.m. EDT |
Poster Presentation
| Title | Lead Author | Presentation details |
|---|---|---|
| SOUND-C2 interim analysis: The efficacy and safety of the interferon-free combination of BI 201335 and BI 207127 in genotype-1 HCV patients with cirrhosis | V. Soriano | Late Breaker Poster# 1420 Date: Thur, April 19 Time: 12:00 - 1:30 p.m. CEST/ 6:00 - 7:30 a.m. EDT |
| Characterization of HCV NS3 variants that emerged during virologic breakthrough and relapse from BI 201335 Phase 2 SILEN-C2 study in pegylated-interferon plus ribavirin treatment-experienced patients | G. Kukolj | Poster# 1185 Date: Sat, April 21 Time: 12:30 - 1:30 p.m. CEST/ 6:30 - 7:30 a.m. EDT |
| Impact of early response definitions on duration and outcome of treatment with BI 201335 plus pegylated-interferon plus ribavirin | M. Sulkowski | Poster# 1209 Date: Sat, April 21 Time: 12:30 - 1:30 p.m CEST/ 6:30 - 7:30 a.m. EDT |
| Preclinical characterization of the hepatitis C virus NS5B polymerase non-nucleoside inhibitor BI 207127 | P. Beaulieu | Poster #822 Date: Fri, April 20 Time: 12:30 - 2:00 p.m. CEST/ 6:30 - 8:00 a.m. EDT |
About Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.
For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at http://twitter.com/boehringerus.
No comments:
Post a Comment